LLMs in me

LLMs in mental health care show promise but evidence still too uncertain for routine use

BACKGROUND General-purpose large language models (LLMs) are increasingly being tested in mental health care, where language is central to assessment, diagnosis, risk evaluation, therapeutic interaction, monitoring, and patient education. However, their clinical usefulness, safety, and readiness for implementation remain uncertain. Existing reviews have largely been descriptive or scoping in nature, and broad health care reviews have not examined in detail the distinctive risks and applications of LLMs in mental health care. OBJECTIVE We aim to systematically review empirical evidence

ECG foundation model shows broad potential for cardiovascular diagnosis

A large-scale ECG foundation model trained on more than 1.7 million ECGs paired with clinician reports consistently outperformed supervised and non-ECG foundation models across cardiovascular diagnosis and prediction tasks. The model, called ECG-C...

GLP-1 RAs linked to lower TB risk in patients with type 2 diabetes

Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) was consistently associated with a lower risk of tuberculosis (TB) in patients with type 2 diabetes (T2D) compared with 4 other commonly prescribed glucose-lowering agents, according to a la...


Sixty Seconds Science


Spotify episodes

Apple podcasts

Google podcasts

Partner

Search:
Date
Filters:
2026 ESC G
7:21

2026 ESC Guidelines on Cardiac Rehabilitation

Presenter: Matthias Wilhelm
Cardiology
ESC 2026
5th Univer
7:18

5th Universal Definition of Myocardial Infarction

Presenter: Kristin Newby
Cardiology
ESC 2026
ENRICH-AF:
5:40

ENRICH-AF: Edoxaban in Intracranial Hemorrhage Survivors with Atrial Fibrillation

Presenter: Ashkan Shoamanesh
Cardiology
ESC 2026
SINGLE-AF:
5:24

SINGLE-AF: Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk

Presenter: Boyoung Joung
Cardiology
ESC 2026
From Guide
6:55

From Guidelines to Clinical Impact: GDMT Implementation

Presenter: Giuseppe Rosano
Cardiology
ESC 2026
Main Highl
5:14

Main Highlights and Key Clinical Takeaways of ESC 2026

Presenter: Felix Mahfoud
Cardiology
ESC 2026
Start Earl
6:06

Start Early, Start in Hospital: Translating Heart Failure Guidelines into Practice

Presenter: Shelley Zieroth
Cardiology
ESC 2026
From Guide
7:47

From Guidelines to Clinical Impact: Key Takeaways on GDMT Implementation

Presenter: Piotr Ponikowski
Cardiology
ESC 2026
SWITCH SWE
10:14

SWITCH SWEDEHEART: Switching Ticagrelor to Prasugrel in ACS

Presenter: Elmir Omerovic
Cardiology
ESC 2026
2026 ESC G
6:18

2026 ESC Guidelines for the Management of Heart Failure

Presenter: Marianna Adamo
Cardiology
ESC 2026
Practical
9:35

Practical Implementation of the ESC Atrial Fibrillation Guideline

Presenter: Michiel Rienstra
Cardiology
ESC 2026
2026 ESC G
5:49

2026 ESC Guidelines for the Management of Cardiovascular Disease and Chronic Kidney Disease

Presenter: Kevin Damman
Cardiology
ESC 2026
How to Per
6:49

How to Personalise the Treatment of Atrial Fibrillation

Presenter: Helmut Puererfellner
Cardiology
ESC 2026
Comorbidit
7:47

Comorbidities Require Special Attention in Atrial Fibrillation

Presenter: Ratika Parkash
Cardiology
ESC 2026
LDL Choles
10:40

LDL Cholesterol Management in CAD: From ARMYDA to AMUNDSEN

Presenter: Giuseppe Patti
Cardiology
ESC 2026
REACT: Pre
6:55

REACT: Prevalence of Silent Atherosclerosis Across Adult Life

Presenter: Henning Bundgaard
Cardiology
ESC 2026
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
The import
11:22

The importance of the anterior interface in eye surgery

Presenter: Marie-José Tassignon
Internal Medicine
Haematolog
17:26

Haematology is at the forefront - interview with EHA President

Presenter: Antonio Almeida
Oncology
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Oncology
General as
1:18

General aspects of the ESH2023 Hypertension Guidelines - What are the major changes?

Presenter: Michel Burnier
Cardiology
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
Cardiology
How to tre
1:06

How to treat patients optimally with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
Oncology
How novel
1:07

How novel AI model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia?

Presenter: Andrew Srisuwananukorn
Hematology
The future
1:10

The future of Multiple Myeloma management

Presenter: Xavier Leleu
Hematology
Benefits o
1:01

Benefits of myeloma regimens in the real world fall well short of trials

Presenter: Alissa Visram
Hematology
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
Cardiology
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
Cardiology
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Cardiology
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
Cardiology
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Cardiology
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Oncology